Показано 0 из 0
Дата |
---|
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
19.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
4.10
|
5.06
|
4.15
|
4.15
|
4.20
|
4.20
|
|
|
626.55
|
15.00
|
4.04
|
5.06
|
4.14
|
4.10
|
4.14
|
4.11
|
|
|
1 517.24
|
16.00
|
3.94
|
5.06
|
4.19
|
4.02
|
4.21
|
4.02
|
|
|
3 394.92
|
11.00
|
3.95
|
5.06
|
4.29
|
4.115
|
4.29
|
4.115
|
|
|
756.25
|
12.00
|
4.15
|
5.00
|
4.47
|
4.29
|
4.47
|
4.29
|
|
|
6 030.35
|
14.00
|
4.15
|
4.48
|
4.45
|
4.365
|
4.45
|
4.365
|
|
|
714.49
|
6.00
|
4.15
|
4.77
|
4.47
|
4.36
|
4.49
|
4.40
|
|
|
13 149.48
|
10.00
|
4.16
|
4.75
|
4.41
|
4.41
|
4.43
|
4.425
|
|
|
7 749.30
|
14.00
|
4.08
|
4.76
|
4.27
|
4.19
|
4.27
|
4.19
|
|
|
12.75
|
4.00
|
4.03
|
4.75
|
4.10
|
4.05
|
4.22
|
4.13
|
|
|
16 600.75
|
15.00
|
Marker Therapeutics, Inc., formerly known as TapImmune, Inc., is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets.